Silence Therapeutics (SLN) News Today $5.65 +0.28 (+5.21%) As of 03:28 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock SLN Latest News All Sources Trusted Sources MarketBeat Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 Time Period Wall Street Zen Upgrades Silence Therapeutics (NASDAQ:SLN) to "Hold"June 16 at 1:31 AM | americanbankingnews.comSilence Therapeutics' (SLN) "Buy" Rating Reiterated at Chardan CapitalJune 16 at 1:31 AM | americanbankingnews.comSilence Therapeutics' (SLN) "Buy" Rating Reaffirmed at HC WainwrightJune 15 at 1:45 AM | americanbankingnews.comSilence Therapeutics (NASDAQ:SLN) Rating Increased to Hold at Wall Street ZenWall Street Zen raised shares of Silence Therapeutics from a "sell" rating to a "hold" rating in a research note on Saturday.June 14, 2025 | marketbeat.comHC Wainwright Reiterates "Buy" Rating for Silence Therapeutics (NASDAQ:SLN)HC Wainwright reissued a "buy" rating and set a $75.00 price target on shares of Silence Therapeutics in a research report on Friday.June 13, 2025 | marketbeat.comSilence Therapeutics (NASDAQ:SLN) Receives Buy Rating from Chardan CapitalChardan Capital reaffirmed a "buy" rating and issued a $35.00 price objective on shares of Silence Therapeutics in a report on Friday.June 13, 2025 | marketbeat.comSilence Therapeutics Presents Additional Phase 1 Data Highlighting Promise of Divesiran as the Potential First-in-Class siRNA Treatment for Polycythemia VeraJune 12, 2025 | businesswire.comBrokerages Set Silence Therapeutics plc (NASDAQ:SLN) PT at $33.83June 10, 2025 | americanbankingnews.comSilence Therapeutics plc (NASDAQ:SLN) Receives Average Rating of "Moderate Buy" from AnalystsShares of Silence Therapeutics plc (NASDAQ:SLN - Get Free Report) have received a consensus rating of "Moderate Buy" from the seven ratings firms that are currently covering the firm, MarketBeat reports. One research analyst has rated the stock with a sell recommendation and six have assigned a bJune 7, 2025 | marketbeat.comSilence Therapeutics plc (NASDAQ:SLN) Short Interest UpdateSilence Therapeutics plc (NASDAQ:SLN - Get Free Report) saw a large decline in short interest in the month of May. As of May 15th, there was short interest totalling 1,250,000 shares, a decline of 15.0% from the April 30th total of 1,470,000 shares. Based on an average daily volume of 228,700 shares, the short-interest ratio is currently 5.5 days. Approximately 4.2% of the shares of the company are sold short.June 4, 2025 | marketbeat.comMillennium Management LLC Reduces Stock Position in Silence Therapeutics plc (NASDAQ:SLN)Millennium Management LLC lessened its stake in shares of Silence Therapeutics plc (NASDAQ:SLN - Free Report) by 57.3% during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 473,552 shares of the company's stocJune 1, 2025 | marketbeat.comSilence Therapeutics plc (NASDAQ:SLN) Shares Acquired by Bank of America Corp DEBank of America Corp DE grew its stake in Silence Therapeutics plc (NASDAQ:SLN - Free Report) by 48,165.6% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 499,066 shares of the company's stock after purchaJune 1, 2025 | marketbeat.comSilence Therapeutics plc (NASDAQ:SLN) Shares Bought by Woodline Partners LPWoodline Partners LP boosted its holdings in shares of Silence Therapeutics plc (NASDAQ:SLN - Free Report) by 22.6% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 498,732 shares of the company's stockMay 27, 2025 | marketbeat.comPoint72 Asset Management L.P. Has $4.36 Million Stock Position in Silence Therapeutics plc (NASDAQ:SLN)Point72 Asset Management L.P. increased its stake in shares of Silence Therapeutics plc (NASDAQ:SLN - Free Report) by 35.3% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 633,100 shares of the company'May 22, 2025 | marketbeat.comSilence Therapeutics plc (NASDAQ:SLN) Receives Average Recommendation of "Moderate Buy" from AnalystsShares of Silence Therapeutics plc (NASDAQ:SLN - Get Free Report) have been assigned a consensus rating of "Moderate Buy" from the seven brokerages that are presently covering the stock, MarketBeat.com reports. One research analyst has rated the stock with a sell rating and six have assigned a buMay 15, 2025 | marketbeat.comIntegral Health Asset Management LLC Takes Position in Silence Therapeutics plc (NASDAQ:SLN)Integral Health Asset Management LLC acquired a new stake in shares of Silence Therapeutics plc (NASDAQ:SLN - Free Report) in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 200,000 shares of the company'sMay 14, 2025 | marketbeat.comWhat is William Blair's Forecast for SLN FY2027 Earnings?Silence Therapeutics plc (NASDAQ:SLN - Free Report) - William Blair boosted their FY2027 earnings per share estimates for shares of Silence Therapeutics in a note issued to investors on Thursday, May 8th. William Blair analyst M. Minter now anticipates that the company will post earnings of $13.6May 14, 2025 | marketbeat.comSilence Therapeutics (NASDAQ:SLN) Price Target Lowered to $35.00 at Chardan CapitalChardan Capital dropped their price objective on shares of Silence Therapeutics from $55.00 to $35.00 and set a "buy" rating for the company in a research note on Friday.May 11, 2025 | marketbeat.comSilence Therapeutics (SLN) Projected to Post Quarterly Earnings on ThursdaySilence Therapeutics (NASDAQ:SLN) will be releasing its Q1 2025 earnings before the market opens on Thursday, May 15. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2025-5-15-silence-therapeutics-plc-stock/)May 10, 2025 | marketbeat.comSilence Therapeutics plc GAAP EPS of -C$0.20May 8, 2025 | seekingalpha.comCantor Fitzgerald L. P. Buys 205,534 Shares of Silence Therapeutics plc (NASDAQ:SLN)Cantor Fitzgerald L. P. raised its stake in Silence Therapeutics plc (NASDAQ:SLN - Free Report) by 61.5% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 539,726 shares of the company's stock after buying an additionalMay 7, 2025 | marketbeat.comSilence Therapeutics plc: Silence Therapeutics Welcomes Tim McInerney to Board of DirectorsMay 6, 2025 | finanznachrichten.deSilence Therapeutics Welcomes Tim McInerney to Board of DirectorsMay 6, 2025 | businesswire.comSilence Therapeutics plc (NASDAQ:SLN) Stock Holdings Increased by Nantahala Capital Management LLCNantahala Capital Management LLC boosted its position in Silence Therapeutics plc (NASDAQ:SLN - Free Report) by 424.8% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 1,049,676 shares of the company's stocApril 30, 2025 | marketbeat.comBoothbay Fund Management LLC Has $2.42 Million Position in Silence Therapeutics plc (NASDAQ:SLN)Boothbay Fund Management LLC grew its stake in Silence Therapeutics plc (NASDAQ:SLN - Free Report) by 105.4% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 351,527 shares of the company's sApril 30, 2025 | marketbeat.comMarshall Wace LLP Purchases 320,472 Shares of Silence Therapeutics plc (NASDAQ:SLN)Marshall Wace LLP lifted its position in Silence Therapeutics plc (NASDAQ:SLN - Free Report) by 190.3% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 488,889 shares of the company's stock after acquiring an additional 320,472April 28, 2025 | marketbeat.comSilence Therapeutics plc (SLN): Among Takeover Rumors Hedge Funds Are BuyingApril 23, 2025 | insidermonkey.comSilence Therapeutics plc (NASDAQ:SLN) Given Average Rating of "Moderate Buy" by BrokeragesSilence Therapeutics plc (NASDAQ:SLN - Get Free Report) has earned an average recommendation of "Moderate Buy" from the seven ratings firms that are currently covering the firm, MarketBeat.com reports. One research analyst has rated the stock with a sell rating and six have issued a buy rating onApril 20, 2025 | marketbeat.comSilence Therapeutics (NASDAQ:SLN) Earns "Buy" Rating from HC WainwrightHC Wainwright reiterated a "buy" rating and issued a $75.00 target price on shares of Silence Therapeutics in a report on Friday.March 8, 2025 | marketbeat.comSilence Therapeutics (NASDAQ:SLN) Given New $45.00 Price Target at Morgan StanleyMorgan Stanley reduced their price target on shares of Silence Therapeutics from $49.00 to $45.00 and set an "overweight" rating for the company in a research note on Wednesday.March 6, 2025 | marketbeat.comBMO Capital Markets Cuts Silence Therapeutics (NASDAQ:SLN) Price Target to $25.00BMO Capital Markets lowered their target price on shares of Silence Therapeutics from $67.00 to $25.00 and set an "outperform" rating on the stock in a research report on Tuesday.March 5, 2025 | marketbeat.comSilence Therapeutics to Webcast Presentation at the Leerink Partners Global Healthcare ConferenceMarch 5, 2025 | businesswire.comSilence Therapeutics (SLN) Expected to Announce Quarterly Earnings on WednesdaySilence Therapeutics (NASDAQ:SLN) will be releasing earnings before the market opens on Wednesday, March 12. (Register for Conference Call at http://mmm.wallstreethorizon.com/u.asp?u=666107)March 5, 2025 | marketbeat.comThe Goldman Sachs Group Cuts Silence Therapeutics (NASDAQ:SLN) Price Target to $4.00The Goldman Sachs Group cut their target price on Silence Therapeutics from $6.00 to $4.00 and set a "sell" rating on the stock in a research note on Tuesday.March 4, 2025 | marketbeat.comSilence Therapeutics Full Year 2024 Earnings: Revenues Beat Expectations, EPS LagsMarch 1, 2025 | uk.finance.yahoo.comSilence Therapeutics (NASDAQ:SLN) Announces Quarterly Earnings Results, Beats Estimates By $0.43 EPSSilence Therapeutics (NASDAQ:SLN - Get Free Report) released its earnings results on Thursday. The company reported $0.27 earnings per share for the quarter, beating analysts' consensus estimates of ($0.16) by $0.43. Silence Therapeutics had a negative return on equity of 62.81% and a negative net margin of 342.00%.February 28, 2025 | marketbeat.comSilence Therapeutics plc (SLN) Q4 2024 Earnings Call TranscriptFebruary 28, 2025 | seekingalpha.comSilence Therapeutics Reports Full Year 2024 Financial Results and Provides Business UpdateFebruary 27, 2025 | businesswire.comSilence Therapeutics plc (NASDAQ:SLN) Given Average Recommendation of "Moderate Buy" by AnalystsSilence Therapeutics plc (NASDAQ:SLN - Get Free Report) has earned an average recommendation of "Moderate Buy" from the seven research firms that are covering the stock, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell rating and six have assigned a buy raFebruary 27, 2025 | marketbeat.comSilence Therapeutics (SLN) Expected to Announce Quarterly Earnings on ThursdaySilence Therapeutics (NASDAQ:SLN) will be releasing earnings before the market opens on Thursday, February 27, Financial Modeling Prep reports.February 21, 2025 | marketbeat.comShort Interest in Silence Therapeutics plc (NASDAQ:SLN) Rises By 15.0%Silence Therapeutics plc (NASDAQ:SLN - Get Free Report) saw a large increase in short interest in the month of January. As of January 31st, there was short interest totalling 1,300,000 shares, an increase of 15.0% from the January 15th total of 1,130,000 shares. Based on an average daily volume of 565,200 shares, the days-to-cover ratio is presently 2.3 days.February 16, 2025 | marketbeat.comGoldman Sachs Initiates Coverage of Silence Therapeutics plc - Depositary Receipt () (SLN) with Sell RecommendationFebruary 11, 2025 | msn.comSilence Therapeutics hit with new Sell at Goldman Sachs on resource constraintsFebruary 11, 2025 | seekingalpha.comSilence Therapeutics initiated with a Sell at Goldman SachsFebruary 11, 2025 | markets.businessinsider.comGoldman starts Silence Therapeutics at Sell on ‘undifferentiated’ dataFebruary 11, 2025 | markets.businessinsider.comGoldman Sachs cuts Silence Therapeutics stock rating to SellFebruary 11, 2025 | msn.comThe Goldman Sachs Group Begins Coverage on Silence Therapeutics (NASDAQ:SLN)The Goldman Sachs Group initiated coverage on Silence Therapeutics in a report on Tuesday. They issued a "sell" rating and a $6.00 target price on the stock.February 11, 2025 | marketbeat.comHC Wainwright Has Negative Outlook of SLN FY2024 EarningsSilence Therapeutics plc (NASDAQ:SLN - Free Report) - HC Wainwright dropped their FY2024 earnings per share estimates for shares of Silence Therapeutics in a note issued to investors on Wednesday, January 29th. HC Wainwright analyst P. Trucchio now anticipates that the company will post earningsFebruary 3, 2025 | marketbeat.comSilence Therapeutics plc (NASDAQ:SLN) Receives Average Rating of "Buy" from BrokeragesSilence Therapeutics plc (NASDAQ:SLN - Get Free Report) has received a consensus recommendation of "Buy" from the six ratings firms that are currently covering the firm, Marketbeat Ratings reports. Six analysts have rated the stock with a buy recommendation. The average 12-month target price amongFebruary 2, 2025 | marketbeat.comAnalysts Issue Forecasts for SLN FY2029 EarningsSilence Therapeutics plc (NASDAQ:SLN - Free Report) - HC Wainwright issued their FY2029 earnings per share (EPS) estimates for Silence Therapeutics in a report released on Wednesday, January 29th. HC Wainwright analyst P. Trucchio forecasts that the company will earn $0.66 per share for the year.January 31, 2025 | marketbeat.com Get Silence Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for SLN and its competitors with MarketBeat's FREE daily newsletter. Email Address SLN Media Mentions By Week SLN Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. SLN News Sentiment▼0.370.56▲Average Medical News Sentiment SLN News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. SLN Articles This Week▼92▲SLN Articles Average Week Get Silence Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for SLN and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies UPB News DNTH News MAZE News SANA News KURA News RLAY News VERV News ALT News BCYC News KROS News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:SLN) was last updated on 6/18/2025 by MarketBeat.com Staff From Our PartnersElon’s BIGGEST warning yet?Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… ...Brownstone Research | SponsoredYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | SponsoredWhen This Happens, You Don’t Wait. You Act.This same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredAn AI run of epic proportions is only getting startedI just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredTrump Makes Major Crypto AnnouncementPay close attention to what I'm about to share… Most investors think Trump's pro-crypto policies will lift ...Crypto 101 Media | SponsoredElon’s End Game Is Going Live -- And It Could Make You a FortuneThe media and the so-called experts have laughed at Elon Musk his entire career. CBS called PayPal “one of ...The Oxford Club | SponsoredSorry about the swear wordWhat a huge few months for Bitcoin. First, Bitcoin hit $100,000… Then, Donald Trump pledged to create an...Manward Press | SponsoredThe Dollar Reset Nobody’s Talking AboutCould this man take down the financial system? In March, the Senate granted sweeping powers to a Harvard ec...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Silence Therapeutics PLC Sponsored ADR Please log in to your account or sign up in order to add this asset to your watchlist. Share Silence Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy SLN Stock Free SLN Stock Alerts